JP2019507135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507135A5 JP2019507135A5 JP2018540141A JP2018540141A JP2019507135A5 JP 2019507135 A5 JP2019507135 A5 JP 2019507135A5 JP 2018540141 A JP2018540141 A JP 2018540141A JP 2018540141 A JP2018540141 A JP 2018540141A JP 2019507135 A5 JP2019507135 A5 JP 2019507135A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- binding substance
- targeting moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291776P | 2016-02-05 | 2016-02-05 | |
| US201662291774P | 2016-02-05 | 2016-02-05 | |
| US201662291779P | 2016-02-05 | 2016-02-05 | |
| US201662291769P | 2016-02-05 | 2016-02-05 | |
| US201662291772P | 2016-02-05 | 2016-02-05 | |
| US62/291,776 | 2016-02-05 | ||
| US62/291,779 | 2016-02-05 | ||
| US62/291,774 | 2016-02-05 | ||
| US62/291,769 | 2016-02-05 | ||
| US62/291,772 | 2016-02-05 | ||
| US201662336030P | 2016-05-13 | 2016-05-13 | |
| US201662335979P | 2016-05-13 | 2016-05-13 | |
| US201662335880P | 2016-05-13 | 2016-05-13 | |
| US201662335968P | 2016-05-13 | 2016-05-13 | |
| US201662335965P | 2016-05-13 | 2016-05-13 | |
| US62/335,979 | 2016-05-13 | ||
| US62/336,030 | 2016-05-13 | ||
| US62/335,968 | 2016-05-13 | ||
| US62/335,965 | 2016-05-13 | ||
| US62/335,880 | 2016-05-13 | ||
| US201662353607P | 2016-06-23 | 2016-06-23 | |
| US62/353,607 | 2016-06-23 | ||
| US201662411805P | 2016-10-24 | 2016-10-24 | |
| US62/411,805 | 2016-10-24 | ||
| PCT/EP2017/052553 WO2017134306A1 (en) | 2016-02-05 | 2017-02-06 | Cd8 binding agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507135A JP2019507135A (ja) | 2019-03-14 |
| JP2019507135A5 true JP2019507135A5 (https=) | 2020-03-19 |
| JP6991979B2 JP6991979B2 (ja) | 2022-03-04 |
Family
ID=57995193
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541357A Active JP7030704B2 (ja) | 2016-02-05 | 2017-02-06 | 二重特異性シグナル伝達物質およびその使用 |
| JP2018541289A Active JP7166923B2 (ja) | 2016-02-05 | 2017-02-06 | 標的療法剤およびその使用 |
| JP2018540141A Active JP6991979B2 (ja) | 2016-02-05 | 2017-02-06 | Ｃｄ８結合物質 |
| JP2018541133A Active JP7236273B2 (ja) | 2016-02-05 | 2017-02-06 | Ｃｌｅｃ９ａ結合物質 |
| JP2022025686A Active JP7386277B2 (ja) | 2016-02-05 | 2022-02-22 | 二重特異性シグナル伝達物質およびその使用 |
| JP2022110687A Pending JP2022153437A (ja) | 2016-02-05 | 2022-07-08 | 標的療法剤およびその使用 |
| JP2024133824A Pending JP2024164840A (ja) | 2016-02-05 | 2024-08-09 | 標的療法剤およびその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541357A Active JP7030704B2 (ja) | 2016-02-05 | 2017-02-06 | 二重特異性シグナル伝達物質およびその使用 |
| JP2018541289A Active JP7166923B2 (ja) | 2016-02-05 | 2017-02-06 | 標的療法剤およびその使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541133A Active JP7236273B2 (ja) | 2016-02-05 | 2017-02-06 | Ｃｌｅｃ９ａ結合物質 |
| JP2022025686A Active JP7386277B2 (ja) | 2016-02-05 | 2022-02-22 | 二重特異性シグナル伝達物質およびその使用 |
| JP2022110687A Pending JP2022153437A (ja) | 2016-02-05 | 2022-07-08 | 標的療法剤およびその使用 |
| JP2024133824A Pending JP2024164840A (ja) | 2016-02-05 | 2024-08-09 | 標的療法剤およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (7) | US11001631B2 (https=) |
| EP (8) | EP3411398B1 (https=) |
| JP (7) | JP7030704B2 (https=) |
| CN (9) | CN109071627B (https=) |
| CA (4) | CA3013554A1 (https=) |
| DK (3) | DK3411065T3 (https=) |
| ES (3) | ES2981745T3 (https=) |
| WO (4) | WO2017134302A2 (https=) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11001631B2 (en) * | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| CN109563141A (zh) * | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| EP3577133A1 (en) * | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| US20210017247A1 (en) | 2017-07-03 | 2021-01-21 | Torque Therapeutics, Inc. | Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof |
| DK3661954T3 (da) | 2017-08-03 | 2022-04-19 | Amgen Inc | Interleukin-21-muteiner og fremgangsmåder til behandling |
| EP3665201A4 (en) * | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| US12091463B2 (en) | 2017-08-09 | 2024-09-17 | Orionis Biosciences, Inc. | Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH) |
| AU2018318698A1 (en) * | 2017-08-16 | 2020-02-20 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16, and EGFR, HLA-E CCR4, or PD-L1 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| WO2020113403A1 (en) * | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| JP7534215B2 (ja) | 2018-01-24 | 2024-08-14 | ベイジン パーカンズ オンコロジー カンパニー リミテッド | サイトカイン融合タンパク質 |
| US20200354424A1 (en) * | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| JP2021513361A (ja) * | 2018-02-05 | 2021-05-27 | オリオニス バイオサイエンシーズ，インコーポレイテッド | 線維芽細胞結合物質およびその使用 |
| US20210024631A1 (en) * | 2018-03-28 | 2021-01-28 | Orionis Biosciences, Inc. | Bi-functional proteins and construction thereof |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| MX2020011023A (es) * | 2018-04-19 | 2021-01-29 | Baylor College Medicine | Reprogramación de células t cd4 en células cd8 citotóxicas por expresión forzada de cd8ab y receptores de células t restringidos de clase 1. |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| KR20210056288A (ko) | 2018-06-01 | 2021-05-18 | 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 | 질환 또는 병태를 치료하기 위한 조성물 및 그의 용도 |
| CN115991787A (zh) | 2018-06-05 | 2023-04-21 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
| US20210347849A1 (en) * | 2018-07-24 | 2021-11-11 | Good T Cells, Inc. | Composition for Preventing or Treating Immune-Related Diseases |
| EP3826673A4 (en) * | 2018-07-26 | 2022-03-09 | Tayu Huaxia Biotech Medical Group Co., Ltd. | COMPOSITIONS AND METHODS FOR IMAGING |
| WO2020033646A1 (en) * | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF |
| EP3841112A1 (en) | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| WO2020048454A1 (zh) * | 2018-09-04 | 2020-03-12 | 南京优迈生物科技有限公司 | 融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用 |
| US12162947B2 (en) * | 2018-09-04 | 2024-12-10 | Nanjing Umab-Biopharma Co., Ltd. | Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection |
| WO2020077257A1 (en) * | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| BR112021012027A2 (pt) * | 2018-12-21 | 2021-11-03 | Ose Immunotherapeutics | Molécula bifuncional direcionada contra pd-1 humano |
| CN113614109A (zh) * | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| WO2020146393A1 (en) * | 2019-01-07 | 2020-07-16 | Shattuck Labs. Inc. | Heterodimeric proteins for modulating gamma delta t cells |
| WO2020151572A1 (en) | 2019-01-23 | 2020-07-30 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-pd-l1 diabodies and the use thereof |
| CN111499718B (zh) * | 2019-01-30 | 2022-06-14 | 复旦大学 | 人α干扰素受体结合相关位点突变体及其用途 |
| WO2020187152A1 (zh) * | 2019-03-15 | 2020-09-24 | 正大天晴药业集团股份有限公司 | 治疗小细胞肺癌的联用药物组合物 |
| JP7729778B2 (ja) * | 2019-03-28 | 2025-08-26 | オリオニス バイオサイエンシズ，インコーポレイテッド | Ｆｍｓ様チロシンキナーゼ３（ｆｌｔ３）に対するキメラタンパク質およびキメラタンパク質複合体 |
| CA3133648A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| CN120590542A (zh) * | 2019-03-28 | 2025-09-05 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| JP7689079B2 (ja) * | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| AU2020287373B2 (en) * | 2019-06-05 | 2026-01-29 | Asher Biotherapeutics, Inc. | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function |
| WO2020249003A1 (en) * | 2019-06-10 | 2020-12-17 | Apollomics Inc. (Hangzhou) | Antibody-interleukin fusion protein and methods of use |
| WO2020257412A1 (en) * | 2019-06-19 | 2020-12-24 | Orionis Biosciences, Inc. | Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes |
| WO2021037184A1 (zh) * | 2019-08-30 | 2021-03-04 | 正大天晴药业集团南京顺欣制药有限公司 | 一种靶向PD-L1和TGF-β的融合蛋白及其用途 |
| WO2021046159A1 (en) * | 2019-09-04 | 2021-03-11 | Genentech, Inc. | Cd8 binding agents and uses thereof |
| EP4034146A4 (en) * | 2019-09-26 | 2024-03-06 | Orionis Biosciences, Inc. | CONJUGATED CHIMERIC PROTEINS |
| AU2020353660A1 (en) * | 2019-09-26 | 2022-04-14 | Orionis Biosciences, Inc. | PD-L1 targeted chimeric proteins and uses thereof |
| KR102402276B1 (ko) * | 2019-11-15 | 2022-05-26 | 주식회사 제넥신 | 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도 |
| KR20220109436A (ko) | 2019-12-03 | 2022-08-04 | 에보텍 인터내셔널 게엠베하 | 인터페론-결합된 항원 결합 단백질 및 이의 용도 |
| CN118562007A (zh) * | 2019-12-19 | 2024-08-30 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| DE102020111571A1 (de) * | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| IL298695A (en) * | 2020-06-02 | 2023-02-01 | Childrens Medical Center | Nanobody conjugates (VHH) and their uses |
| WO2022002153A1 (zh) * | 2020-06-30 | 2022-01-06 | 正大天晴药业集团股份有限公司 | 用于治疗肿瘤的药物 |
| EP4178609A4 (en) * | 2020-07-07 | 2024-07-24 | Orionis Biosciences, Inc. | IMMUNOSTIMULATORY ADJUVANTS |
| JP2023541601A (ja) | 2020-09-10 | 2023-10-03 | プレシリックス・ナームローゼ・ベンノートシヤープ | Ｆａｐに対する抗体フラグメント |
| TW202231292A (zh) * | 2020-10-13 | 2022-08-16 | 美商健生生物科技公司 | 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法 |
| EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| WO2022111618A1 (zh) * | 2020-11-26 | 2022-06-02 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物 |
| WO2022111562A1 (zh) * | 2020-11-26 | 2022-06-02 | 上海医药集团生物治疗技术有限公司 | 一种经修饰的免疫细胞及其应用 |
| WO2022129313A1 (en) * | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | Precursor proteins and kit for targeted therapy |
| CN112724199B (zh) * | 2020-12-30 | 2023-01-24 | 郑州大学 | 亲和Clec9a的多肽及其应用 |
| EP4274901A1 (en) | 2021-01-11 | 2023-11-15 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| US20240101673A1 (en) | 2021-02-03 | 2024-03-28 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| WO2023125729A1 (zh) * | 2021-12-31 | 2023-07-06 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| CN115583995B (zh) * | 2022-01-30 | 2024-12-13 | 立凌生物制药(苏州)有限公司 | 双特异性抗体及其制备方法和应用 |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023154785A2 (en) * | 2022-02-10 | 2023-08-17 | Orionis Biosciences, Inc. | Il-2 trap molecules |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| CA3251753A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | PRE-TARGETTING |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| US20260098062A1 (en) | 2022-09-21 | 2026-04-09 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| JP2024047762A (ja) | 2022-09-27 | 2024-04-08 | セイコーエプソン株式会社 | 成形用材料 |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024145108A1 (en) * | 2022-12-28 | 2024-07-04 | Binacea Pharma, Inc. | Anti-cd8 antibodies and methods of use thereof |
| WO2024156881A1 (en) | 2023-01-27 | 2024-08-02 | Vib Vzw | CD8b-BINDING POLYPEPTIDES |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| AR132623A1 (es) * | 2023-05-08 | 2025-07-16 | Hoffmann La Roche | PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN116875550B (zh) * | 2023-09-08 | 2023-12-26 | 天津市肿瘤医院（天津医科大学肿瘤医院） | 一种FABP4+C1q+巨噬细胞及其制备方法和用途 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025260013A1 (en) | 2024-06-13 | 2025-12-18 | Yale University | Compositions and methods of mrna-based adjuvants for mrna vaccines |
| CN121378484A (zh) * | 2024-10-14 | 2026-01-23 | 北京大学 | 抗原结合蛋白及其应用 |
| CN120248112B (zh) * | 2025-06-04 | 2025-08-05 | 天津龙晟生物科技有限公司 | 一种叶酸单克隆抗体及其应用以及一种叶酸检测试剂盒 |
| CN120699170B (zh) * | 2025-08-22 | 2025-11-25 | 中生康元生物科技(北京)有限公司 | 一种三特异性单链抗体及其用途 |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4537776A (en) | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| ATE122238T1 (de) | 1987-06-10 | 1995-05-15 | Dana Farber Cancer Inst Inc | Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| ES2055445T3 (es) | 1989-08-22 | 1994-08-16 | Immunex Corp | Proteinas de fusion que comprenden gm-csf e il-3. |
| AU6642390A (en) | 1989-10-27 | 1991-05-31 | Arch Development Corporation | Methods and compositions for promoting immunopotentiation |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| EP0786469B1 (en) | 1990-06-11 | 2006-03-01 | Gilead Sciences, Inc. | Methods of use of nucleic acid ligands |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| SE9201966D0 (sv) | 1992-06-25 | 1992-06-25 | Trion Forskning & Utveckling | Interleukin-1beta deletion mutant |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| WO1996002561A1 (en) | 1994-07-20 | 1996-02-01 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| AU6961796A (en) | 1995-09-12 | 1997-04-01 | Chiron Corporation | Improved interleukin-6 receptor antagonist |
| EP0770397B1 (en) | 1995-10-18 | 2004-04-21 | Akzo Nobel N.V. | Newcastle disease virus combination vaccine |
| US5716946A (en) | 1996-02-13 | 1998-02-10 | Wisconsin Alumni Research Foundation | Multiple sclerosis treatment |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5986059A (en) | 1996-06-14 | 1999-11-16 | Bayer Corporation | T-cell selective interleukin-4 agonists |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO1999037681A2 (en) | 1998-01-26 | 1999-07-29 | Unilever Plc | Method for producing antibody fragments |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| DE60013767T3 (de) | 1999-01-19 | 2009-07-09 | Unilever N.V. | Verfahren zur herstellung von antikörperfragmenten |
| EP1696038B1 (en) | 1999-05-05 | 2010-06-02 | Phylogica Limited | Isolating biological modulators from biodiverse gene fragment libraries |
| AU4761100A (en) | 1999-05-26 | 2000-12-18 | Kalle Saksela | Methods and materials for generating sh3 domains with tailored binding properties |
| JP2001026545A (ja) * | 1999-07-09 | 2001-01-30 | Takara Shuzo Co Ltd | 免疫応答活性化製剤 |
| EP1210424B1 (en) | 1999-08-23 | 2007-02-07 | Dana-Farber Cancer Institute, Inc. | Novel b7-4 molecules and uses therefor |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| US6613756B2 (en) | 2000-05-05 | 2003-09-02 | Wisconsin Alumni Research Foundation | Use of tetracycline derivatives in treating multiple sclerosis |
| SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
| WO2001090190A2 (en) | 2000-05-26 | 2001-11-29 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| GB0014356D0 (en) | 2000-06-12 | 2000-08-02 | Colover Jack | Treatment of multiple sclerosis |
| US20020025304A1 (en) | 2000-06-16 | 2002-02-28 | Croze Edward M. | Novel interferon for the treatment of multiple sclerosis |
| DE60142479D1 (de) | 2000-08-30 | 2010-08-12 | Penn State Res Found | Aminosäureaustauschmutanten von interleukin 13 |
| DE60140474D1 (de) | 2000-09-08 | 2009-12-24 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
| DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| US20040132094A1 (en) | 2000-12-13 | 2004-07-08 | Michael Etzerodt | Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| RU2004109222A (ru) | 2001-08-30 | 2005-10-20 | Байорексис Фармасьютикал Корпорейшн (Us) | Слитые белки модифицированного трансферрина |
| EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CA2501295A1 (en) | 2002-10-02 | 2004-04-15 | Jack Nguyen | Methods of generating and screening for proteases with altered specificity |
| CA2505316C (en) | 2002-11-08 | 2014-08-05 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| CA2508264A1 (en) | 2002-12-05 | 2004-06-24 | Protein Design Labs, Inc. | Methods of treatment of ulcerative colitis with anti-cd3 antibodies |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| WO2004060965A2 (en) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| DK1587907T3 (da) | 2003-01-07 | 2011-04-04 | Dyax Corp | Kunitz-domænebibliotek |
| SI1629011T1 (sl) | 2003-05-31 | 2010-05-31 | Micromet Ag | Humane molekule za vezavo anti hu cd |
| TW200526780A (en) | 2004-01-06 | 2005-08-16 | Hayashibara Biochem Lab | TNF antagonists and TNF inhibitors comprising the same as the active ingredient |
| US20110020273A1 (en) | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| AU2005245918A1 (en) * | 2004-05-19 | 2005-12-01 | F. Hoffmann-La Roche Ag | Interferon-alpha polypeptides and conjugates |
| JP5139800B2 (ja) | 2004-06-03 | 2013-02-06 | ノビミューン エスアー | 抗ｃｄ３抗体およびその使用方法 |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| KR20070020133A (ko) | 2004-07-12 | 2007-02-16 | 미쓰비시덴키 가부시키가이샤 | 광학식 인코더 |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
| CN103169965A (zh) | 2004-11-19 | 2013-06-26 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| WO2006122787A1 (en) | 2005-05-18 | 2006-11-23 | Ablynx Nv | Serum albumin binding proteins |
| CN101355965A (zh) * | 2005-06-08 | 2009-01-28 | 达纳－法伯癌症研究院 | 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物 |
| GB0513047D0 (en) | 2005-06-27 | 2005-08-03 | Thermo Finnigan Llc | Electronic ion trap |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| TW200732347A (en) | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
| WO2008014612A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| EP2102241A2 (en) | 2006-12-15 | 2009-09-23 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| US9023352B2 (en) | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| CN101835802B (zh) | 2007-06-01 | 2014-04-09 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| US20110038865A1 (en) | 2007-06-26 | 2011-02-17 | University Of Miami | Antibody- endostatin fusion protein and its variants |
| GB0805159D0 (en) * | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| EP2109690B9 (en) | 2007-11-29 | 2012-10-24 | MOLECULAR HEALTH GmbH | Eph-b4 specific sirna for reducing epo-induced tumor cell growth during anemia treatment in cancer patients, tissue protective erythropoietin receptor (nepor) and methods of use. |
| WO2009089149A1 (en) | 2008-01-03 | 2009-07-16 | The Johns Hopkins University | B7-h1 (cd274) antagonists induce apoptosis of tumor cells |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| WO2010030671A1 (en) | 2008-09-09 | 2010-03-18 | University Of Medicine And Dentistry Of New Jersey | Type i interferon antagonists |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| JP2012510806A (ja) | 2008-12-08 | 2012-05-17 | コンプリクス エン ヴェー | 単鎖逆平行コイルドコイルタンパク質 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| JP2012521199A (ja) * | 2009-03-23 | 2012-09-13 | ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | 免疫応答を調節するための化合物および方法 |
| ES2534085T3 (es) | 2009-08-17 | 2015-04-17 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| IN2012DN01331A (https=) * | 2009-08-31 | 2015-06-05 | Ibc Pharmaceuticals Inc | |
| US20130115189A1 (en) | 2009-09-10 | 2013-05-09 | Cytos Biotechnology Ag | Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US20110262348A1 (en) | 2010-03-29 | 2011-10-27 | Vrije Universiteit Brussel | Selective targeting of intratumoral cells |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| RU2577299C2 (ru) * | 2011-07-04 | 2016-03-10 | Олег Ильич Эпштейн | Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний |
| HUE029139T2 (hu) | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| SE535863C2 (sv) | 2011-07-18 | 2013-01-22 | Atlas Copco Ind Tech Ab | Hållare för motordrivet verktyg innefattande klämdelar med genomgående hål |
| WO2013053008A2 (en) | 2011-10-14 | 2013-04-18 | The Walter And Eliza Hall Institute Of Medical Research | Molecules which bind clec9a |
| SG10201603411WA (en) * | 2011-10-28 | 2016-07-28 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| CN104245734B (zh) * | 2012-01-20 | 2017-09-05 | 非营利性组织佛兰芒综合大学生物技术研究所 | 靶向突变体α‑螺旋束细胞因子 |
| ES2800426T3 (es) | 2012-03-03 | 2020-12-30 | Immungene Inc | Moléculas de fusión anticuerpos-mutante de interferón modificadas |
| EP2872158A1 (en) | 2012-05-01 | 2015-05-20 | The University of Sydney | Vaccine and uses thereof |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| EP2892924B1 (en) | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| EP2895203A4 (en) | 2012-06-15 | 2016-09-28 | Imaginab Inc | ANTIGENBINDING CONSTRUCTS FOR CD3 |
| US20150191543A1 (en) * | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| WO2014028502A1 (en) * | 2012-08-13 | 2014-02-20 | ImmunGene Inc. | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
| CN102775502A (zh) * | 2012-08-16 | 2012-11-14 | 天津禹王生物医药科技有限公司 | α干扰素融合蛋白 |
| CA2904969C (en) * | 2013-03-13 | 2025-06-17 | Imaginab, Inc. | DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8 |
| JP6541581B2 (ja) | 2013-03-15 | 2019-07-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | 低濃度抗体製剤 |
| MX373245B (es) | 2013-07-05 | 2020-05-11 | Genmab As | Anticuerpos cd3 humanizados o quiméricos. |
| WO2015007536A2 (en) | 2013-07-18 | 2015-01-22 | Vib Vzw | Fusokines involving cytokines with strongly reduced receptor binding affinities |
| CA2918119C (en) | 2013-07-19 | 2022-11-29 | Centre Hospitalier Regional Universitaire De Montpellier | Targeting of ifn.alpha.2 antagonists to treat autoimmune diseases |
| JP6595988B2 (ja) | 2013-07-19 | 2019-10-23 | ヴィブ ブイゼットダブリュー | ターゲットされる修飾ｔｎｆファミリーメンバー |
| DK3022226T3 (en) | 2013-07-19 | 2019-03-25 | Vib Vzw | TARGETED MODIFIED IL-1 FAMILY MEMBERS |
| BR112016002614B8 (pt) * | 2013-08-08 | 2023-11-07 | Hopitaux Paris Assist Publique | Imunocitoquina e composição farmacêutica |
| JP6508785B2 (ja) * | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| CN103536917B (zh) * | 2013-10-30 | 2015-03-11 | 苏州丁孚靶点生物技术有限公司 | 干扰素在治疗肿瘤中的用途及相关的产品和方法 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| UA119352C2 (uk) * | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| WO2016002263A1 (ja) | 2014-06-30 | 2016-01-07 | ソニー株式会社 | 無線通信装置、無線通信方法及びプログラム |
| CA3151221C (en) * | 2014-06-30 | 2026-01-13 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
| EP3168717A4 (en) | 2014-07-11 | 2018-03-14 | Wacom Co., Ltd. | Position indicator, position detection device, and input control method for position detection device |
| CA2955612C (en) * | 2014-07-18 | 2022-05-17 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| US10435470B2 (en) | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| EP2982693A1 (en) | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| DK3209778T3 (da) | 2014-10-24 | 2019-05-27 | Astrazeneca | Kombination |
| CA2965414C (en) * | 2014-10-29 | 2024-01-09 | Teva Pharmaceuticals Australia Pty Ltd | Interferon .alpha.2.beta. variants |
| CN104403004B (zh) * | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| US11001631B2 (en) * | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| US11661455B2 (en) * | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| CN109563141A (zh) * | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
-
2017
- 2017-02-06 US US16/075,318 patent/US11001631B2/en active Active
- 2017-02-06 WO PCT/EP2017/052545 patent/WO2017134302A2/en not_active Ceased
- 2017-02-06 ES ES17705564T patent/ES2981745T3/es active Active
- 2017-02-06 EP EP17704697.6A patent/EP3411398B1/en active Active
- 2017-02-06 CN CN201780021559.4A patent/CN109071627B/zh active Active
- 2017-02-06 CA CA3013554A patent/CA3013554A1/en active Pending
- 2017-02-06 EP EP21195070.4A patent/EP3998281A1/en active Pending
- 2017-02-06 EP EP22160584.3A patent/EP4059957A1/en active Pending
- 2017-02-06 EP EP17704207.4A patent/EP3411397A1/en not_active Withdrawn
- 2017-02-06 JP JP2018541357A patent/JP7030704B2/ja active Active
- 2017-02-06 EP EP17703965.8A patent/EP3411065B1/en active Active
- 2017-02-06 EP EP24168089.1A patent/EP4421094A3/en active Pending
- 2017-02-06 CA CA3013551A patent/CA3013551A1/en active Pending
- 2017-02-06 US US16/075,312 patent/US10988538B2/en active Active
- 2017-02-06 WO PCT/EP2017/052550 patent/WO2017134305A1/en not_active Ceased
- 2017-02-06 JP JP2018541289A patent/JP7166923B2/ja active Active
- 2017-02-06 CN CN201780021264.7A patent/CN109071663B/zh active Active
- 2017-02-06 US US16/075,317 patent/US11236166B2/en active Active
- 2017-02-06 DK DK17703965.8T patent/DK3411065T3/da active
- 2017-02-06 CN CN202310688724.9A patent/CN117024599A/zh active Pending
- 2017-02-06 WO PCT/EP2017/052553 patent/WO2017134306A1/en not_active Ceased
- 2017-02-06 JP JP2018540141A patent/JP6991979B2/ja active Active
- 2017-02-06 EP EP21165264.9A patent/EP3909978A1/en active Pending
- 2017-02-06 JP JP2018541133A patent/JP7236273B2/ja active Active
- 2017-02-06 EP EP17705564.7A patent/EP3411407B1/en active Active
- 2017-02-06 CN CN201780021480.1A patent/CN109071632B/zh active Active
- 2017-02-06 CN CN202310688728.7A patent/CN116769054A/zh active Pending
- 2017-02-06 DK DK17704697.6T patent/DK3411398T3/da active
- 2017-02-06 ES ES17703965T patent/ES2877568T3/es active Active
- 2017-02-06 CA CA3013558A patent/CA3013558C/en active Active
- 2017-02-06 CA CA3013555A patent/CA3013555A1/en active Pending
- 2017-02-06 WO PCT/EP2017/052544 patent/WO2017134301A1/en not_active Ceased
- 2017-02-06 CN CN202211603239.9A patent/CN115850521A/zh active Pending
- 2017-02-06 DK DK17705564.7T patent/DK3411407T3/da active
- 2017-02-06 CN CN201780021194.5A patent/CN108883180B/zh active Active
- 2017-02-06 ES ES17704697T patent/ES2981730T3/es active Active
- 2017-02-06 CN CN202310792348.8A patent/CN116813799A/zh active Pending
- 2017-02-06 CN CN202310792382.5A patent/CN116854826A/zh active Pending
-
2020
- 2020-12-21 US US17/128,599 patent/US20210139586A1/en active Pending
-
2021
- 2021-04-05 US US17/222,043 patent/US12453770B2/en active Active
- 2021-12-17 US US17/554,180 patent/US12364753B2/en active Active
-
2022
- 2022-02-22 JP JP2022025686A patent/JP7386277B2/ja active Active
- 2022-07-08 JP JP2022110687A patent/JP2022153437A/ja active Pending
-
2024
- 2024-08-09 JP JP2024133824A patent/JP2024164840A/ja active Pending
-
2025
- 2025-06-16 US US19/238,731 patent/US20260069686A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507135A5 (https=) | ||
| JP2019507762A5 (https=) | ||
| JP2019506867A5 (https=) | ||
| JP2013502913A5 (https=) | ||
| JP2021503455A5 (https=) | ||
| JP2020525032A5 (https=) | ||
| JP2019116474A5 (https=) | ||
| JP2018512138A5 (https=) | ||
| JP2019510478A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2018508483A5 (https=) | ||
| JP2019531084A5 (https=) | ||
| JP2017048240A5 (https=) | ||
| JP2013506428A5 (https=) | ||
| JP2015163068A5 (https=) | ||
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| JP2017519759A5 (https=) | ||
| JP2009225799A5 (https=) | ||
| JP2020533004A5 (https=) | ||
| JP2018512175A5 (https=) | ||
| JP2009506791A5 (https=) | ||
| Kunz et al. | NANOBODY® molecule, a giga medical tool in nanodimensions | |
| JP2021508707A5 (https=) | ||
| JP2013519364A5 (https=) | ||
| FI3941946T3 (fi) | Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja |